Skip to main content
Premium Trial:

Request an Annual Quote

Myriad, Genetic Technologies Ink Cross-Licensing Pact

NEW YORK, Oct. 28 - Myriad Genetics and Genetic Technologies Limited will cross-license a number of their technologies.


Under the terms of the deal, Myriad will pay GTL $1 million up front plus annual fees for a "broad, non-exclusive" license to its non-coding DNA-analysis and -mapping patents for human diagnostics and therapeutics.


GTL, meantime, will pay "various" undisclosed option fees and annual royalties to market Myriad's diagnostics in Australia and New Zealand.


Click here for more information.

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.